Copeptin assays in children for the differential diagnosis of polyuria-polydipsia syndrome and reference levels in hospitalized children.
child
copeptin
diabetes insipidus
paediatric
polydipsia
polyuria
reference values
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
06
10
2021
received:
05
06
2021
accepted:
10
10
2021
pubmed:
26
10
2021
medline:
28
1
2022
entrez:
25
10
2021
Statut:
ppublish
Résumé
Polyuria-polydipsia syndrome (PPS) is a common presentation in children but the differential diagnosis rests on burdensome water deprivation tests. The aims of this study were to determine a copeptin threshold to distinguish patients with central diabetes insipidus from those with primary polydipsia and to estimate the normal range of copeptin concentrations in children. Single-centre retrospective descriptive study. Two hundred and seventy-eight children aged 2 months to 18 years who consulted for PPS (N = 40) or other reasons (control group, N = 238) at La Timone University Hospital in Marseille, France, between April 2015 and September 2019 and had a copeptin assay. Ultrasensitive copeptin assays on blood samples. Among the children with PPS, the mean copeptin concentrations were 1.72, 55.2 and 15.7 pmol/l in those with central diabetes insipidus (N = 21), nephrogenic diabetes insipidus (N = 3), and primary polydipsia (N = 16), respectively. Copeptin levels lower than 3.53 pmol/l were diagnostic of central diabetes insipidus with 100% sensitivity and 87.4% specificity (p < .001). The 5th-95th copeptin percentile range in the control group was 2.53-21.03 pmol/L. Copeptin levels were significantly higher in boys than in girls but there was no association with age, pubertal stage, body mass index, or the reason for consulting. Our results indicate copeptin assays may be valuable in the differential diagnosis of PPS in children. Larger prospective studies are required to establish their accuracy in everyday clinical practice.
Substances chimiques
Glycopeptides
0
copeptins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-53Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Piffaretti C, Mandereau-Bruno L, Guilmin-Crepon S, Choleau C, Coutant R, Fosse-Edorh S. Trends in childhood type 1 diabetes incidence in France, 2010-2015. Diabetes Res Clin Pract. 2019;149:200-207. doi:10.1016/j.diabres.2018.11.005
Fenske WK, Schnyder I, Koch G, et al. Release and decay kinetics of copeptin vs AVP in response to osmotic alterations in healthy volunteers. J Clin Endocrinol Metab. 2018;103(2):505-513. doi:10.1210/jc.2017-01891
Wun T. Vasopressin and platelets: a concise review. Platelets. 1997;8(1):15-22. doi:10.1080/09537109777492
Kluge M, Riedl S, Erhart-Hofmann B, Hartmann J, Waldhauser F. Improved extraction procedure and RIA for determination of arginine8-vasopressin in plasma: role of premeasurement sample treatment and reference values in children. Clin Chem. 1999;45(1):98-103.
Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states. J Clin Endocrinol Metab. 2011;96(4):1046-1052. doi:10.1210/jc.2010-2499
Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112-119. doi:10.1373/clinchem.2005.060038
Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock. 2007;28(2):219-226. doi:10.1097/SHK.0b013e318033e5da
Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009;66(6):799-808. doi:10.1002/ana.21783
Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009;54(1):60-68. doi:10.1016/j.jacc.2009.01.076
Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly. 2010;140:w13101. doi:10.4414/smw.2010.13101
Katan M, Morgenthaler N, Widmer I, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett. 2008;29(3):341-346.
Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci. 2009;116(3):257-263. doi:10.1042/CS20080140
Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008;19(2):43-49. doi:10.1016/j.tem.2007.11.001
Roussel R, Fezeu L, Marre M, et al. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab. 2014;99(12):4656-4663. doi:10.1210/jc.2014-2295
Enhörning S, Bankir L, Bouby N, et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes. 2013;37(4):598-603. doi:10.1038/ijo.2012.88
Rothermel J, Kulle A, Holterhus P-M, Toschke C, Lass N, Reinehr T. Copeptin in obese children and adolescents: relationships to body mass index, cortisol and gender. Clin Endocrinol. 2016;85(6):868-873. doi:10.1111/cen.13235
Tuli G, Munarin J, Tessaris D, Einaudi S, Matarazzo P, de Sanctis L. Distribution of plasma copeptin levels and influence of obesity in children and adolescents. Eur J Pediatr. 2021;180(1):119-126. doi:10.1007/s00431-020-03777-3
Timper K, Fenske W, Kühn F, et al. Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria-polydipsia syndrome: a prospective multicenter study. J Clin Endocrinol Metab. 2015;100(6):2268-2274. doi:10.1210/jc.2014-4507
Fenske W, Refardt J, Chifu I, et al. A copeptin-based approach in the diagnosis of diabetes insipidus. N Engl J Med. 2018;379(5):428-439. doi:10.1056/NEJMoa1803760
Miller M, Dalakos T, Moses AM, Fellerman H, Streeten DH. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med. 1970;73(5):721-729. doi:10.7326/0003-4819-73-5-721
Tuli G, Tessaris D, Einaudi S, Matarazzo P, Sanctis LD. Copeptin role in polyuria-polydipsia syndrome differential diagnosis and reference range in paediatric age. Clin Endocrinol. 2018;88(6):873-879. doi:10.1111/cen.13583
Schiel R, Perenthaler TJ, Steveling A, Stein G. Plasma copeptin in children and adolescents with type 1 diabetes mellitus in comparison to healthy controls. Diabetes Res Clin Pract. 2016;118:156-161. doi:10.1016/j.diabres.2016.06.019
Du J-M, Sang G, Jiang C-M, He X-J, Han Y. Relationship between plasma copeptin levels and complications of community-acquired pneumonia in preschool children. Peptides. 2013;45:61-65. doi:10.1016/j.peptides.2013.04.015
Fenske W, Quinkler M, Lorenz D, et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome-revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab. 2011;96(5):1506-1515. doi:10.1210/jc.2010-2345
Szego E. ESTEBAN, Étude de santé sur l'environnement, la biosurveillance, l'activité physique et la nutrition 2014-2016. Volet Nutrition. Chapitre Corpulence. Sante Publique France. 2016;64(suppl 4):S175.
Winzeler B, Cesana-Nigro N, Refardt J, et al. Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet. 2019;394(10198):587-595. doi:10.1016/S0140-6736(19)31255-3